{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T18:10:12Z","timestamp":1730916612326,"version":"3.28.0"},"reference-count":24,"publisher":"Georg Thieme Verlag KG","issue":"04","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dtsch Med Wochenschr"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1055\/a-2047-5013","type":"journal-article","created":{"date-parts":[[2024,1,29]],"date-time":"2024-01-29T23:54:28Z","timestamp":1706572468000},"page":"166-173","source":"Crossref","is-referenced-by-count":0,"title":["Aktuelle Therapie der Herzinsuffizienz mit m\u00e4\u00dfiggradig reduzierter und erhaltener Pumpfunktion"],"prefix":"10.1055","volume":"149","author":[{"given":"Stefan","family":"St\u00f6rk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Morbach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2024,1,29]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"TA McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1161\/CIRCULATIONAHA.119.044586","article-title":"Sacubitril\/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure","volume":"141","author":"SD Solomon","year":"2020","journal-title":"Circulation"},{"issue":"37","key":"ref3","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","article-title":"2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"44","author":"TA McDonagh","year":"2023","journal-title":"Eur Heart J"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"B Pitt","year":"2014","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1093\/eurheartj\/ehv464","article-title":"Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction","volume":"37","author":"SD Solomon","year":"2016","journal-title":"Eur Heart J"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1161\/CIRCULATIONAHA.121.056824","article-title":"Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial","volume":"144","author":"M Packer","year":"2021","journal-title":"Circulation"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in Heart Failure with a Preserved Ejection Fraction","volume":"385","author":"SD Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.1002\/ejhf.2064","article-title":"Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trial","volume":"22","author":"SD Anker","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction","volume":"387","author":"SD Solomon","year":"2022","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1038\/s41591-022-02102-9","article-title":"Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trial","volume":"28","author":"O Vardeny","year":"2022","journal-title":"Nat Med"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/S0140-6736(22)01429-5","article-title":"SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials","volume":"400","author":"M Vaduganathan","year":"2022","journal-title":"Lancet"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1002\/ejhf.2810","article-title":"Intravenous iron in patients with heart failure and iron deficiency: an updated meta-analysis","volume":"25","author":"FJ Graham","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1002\/ejhf.1160","article-title":"Effect of digoxin in patients with heart failure and mid-range (borderline) left ventricular ejection fraction","volume":"20","author":"AH Abdul-Rahim","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"3297","DOI":"10.1093\/eurheartj\/ehz641","article-title":"How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)","volume":"40","author":"B Pieske","year":"2019","journal-title":"Eur Heart J"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in Patients with Chronic Kidney Disease","volume":"388","author":"WG Herrington","year":"2023","journal-title":"N Engl J Med"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in Patients with Chronic Kidney Disease","volume":"383","author":"HJL Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes","volume":"383","author":"GL Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes","volume":"385","author":"B Pitt","year":"2021","journal-title":"N Engl J Med"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1016\/S0140-6736(22)02076-1","article-title":"Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial","volume":"400","author":"A Mebazaa","year":"2022","journal-title":"Lancet"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1001\/jamacardio.2018.2936","article-title":"One-Year Safety and Clinical Outcomes of a Transcatheter Interatrial Shunt Device for the Treatment of Heart Failure With Preserved Ejection Fraction in the Reduce Elevated Left Atrial Pressure in Patients With Heart Failure (REDUCE LAP-HF I) Trial: A Randomized Clinical Trial","volume":"3","author":"SJ Shah","year":"2018","journal-title":"JAMA Cardiol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/S0140-6736(11)60101-3","article-title":"Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial","volume":"377","author":"WT Abraham","year":"2011","journal-title":"Lancet"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1016\/S0140-6736(23)00923-6","article-title":"Remote haemodynamic monitoring of pulmonary artery pressures in patients with chronic heart failure (MONITOR-HF): a randomised clinical trial","volume":"401","author":"JJ Brugts","year":"2023","journal-title":"Lancet"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1002\/ejhf.1943","article-title":"Pulmonary artery pressure-guided therapy in ambulatory patients with symptomatic heart failure: the CardioMEMS European Monitoring Study for Heart Failure (MEMS-HF)","volume":"22","author":"CE Angermann","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1007\/s00392-022-01987-3","article-title":"Pulmonary artery sensor system pressure monitoring to improve heart failure outcomes (PASSPORT-HF): rationale and design of the PASSPORT-HF multicenter randomized clinical trial","volume":"111","author":"S St\u00f6rk","year":"2022","journal-title":"Clin Res Cardiol"}],"container-title":["DMW - Deutsche Medizinische Wochenschrift"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2047-5013.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T14:47:19Z","timestamp":1730818039000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2047-5013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,29]]},"references-count":24,"journal-issue":{"issue":"04","published-online":{"date-parts":[[2024,1,29]]},"published-print":{"date-parts":[[2024,2]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2047-5013","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0012-0472","1439-4413"],"issn-type":[{"type":"print","value":"0012-0472"},{"type":"electronic","value":"1439-4413"}],"subject":[],"published":{"date-parts":[[2024,1,29]]}}}